Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript
Source: SeekingAlpha
2026-02-24 17:47:58 ET
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer February 24, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript
ArTara Therapeutics Inc.
NASDAQ: TARA
TARA Trading
-1.95% G/L:
$5.77 Last:
204,379 Volume:
$5.71 Open:
TARA Latest News
February 23, 2026 05:05:00 pm
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
February 17, 2026 08:24:00 am
The FDA Cleared 50 Oncology Approvals in 2025 and the Pipeline Keeps Accelerating
TARA Stock Data
$335,599,804
47,293,757
3.64%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
